Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Not Applicable

Completed

• Conditions: Non-alcoholic Fatty Liver Disease
• Interventions: Other: placebo pills; Other: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin

• Registration Number: NCT02875392
• Lead Sponsor: Taipei Medical University WanFang Hospital

Brief Summary

Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Detailed Description

Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness. The strongest fucoidan among all seaweed for inhibiting cancer cells is in Okinawa Japanese waters. For chemically speaking, the major components for fucoidan consisted of mainly fucose which is a kind of polysaccharide with strong biological activity. However, patients need to take actual fucoidan in order to reach the best effectiveness for inhibiting cancer cell.

Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Study Timeline

• Status Verified: 2016-07
• Study First Submitted: 2016-08-05
• Study First Submitted QC: 2016-08-17
• Study First Posted: 2016-08-23
• Study Start: 2016-11
• Primary Completion: 2017-10
• Study Completion: 2018-03
• Results First Submitted: 2021-01-18
• Results First Submitted QC: 2021-02-23
• Results First Posted: 2021-03-17
• Last Update Submitted: 2021-03-18
• Last Update Posted: 2021-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

• Patients who are aged between 20-75 with non alcoholic fatty liver disease (NAFLD).

Exclusion Criteria

1. Patients were allergic to seafood.
2. Patients who take Vitamin E or Pioglitazone.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo pills	placebo pills	placebo capsule 6 per day (before breakfast and supper)
Fucoidan use	275mg Oligo Fucoidan + 275mg HS Fucoxanthin	FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)

Primary Outcome Measures

Name	Time	Method
Change in ALT Index	6 months	Measure the first month and the sixth-month change in the index which is ALT related to Liver inflammation.
Change in AST Index	6 months	Measure the first month and the sixth-month change in the index which is AST relate to Liver inflammation
Change in HbA1c	6 months	Measure the first month and the sixth-month change in the index which is HbA1c relate to Liver inflammation

Trial Locations

Locations (1)

WanFangH; 🇨🇳 Taipei, Taiwan